Optiscan has entered into a collaboration through a know-how agreement with Mayo Clinic - the largest integrated, not-for-profit medical group practice in the world. The agreement will bring together experts from both companies to develop a robot-compatible endomicroscopic imaging system with an initial focus on robotic-assisted breast cancer surgery. The collaboration combines Optiscan’s engineering expertise in digital endomicroscopic hardware and software development with Mayo Clinic’s know-how in robotic surgery and quality patient care. Learn more.

Optiscan has engaged Prolucid Technologies, a Canadian-based software engineering firm, to co-develop the company’s cloud-based telepathology streaming service and artificial intelligence software-as-a-medical-device for its endomicroscopy suite of products . Learn more.

Optiscan is working with Capgemini (formerly D+I), to co-develop the company’s next generation endomicroscopic imaging platform and device portfolio. Learn more about D+I here.

Optiscan’s confocal imaging technology can be customised for specific medical applications. CONVIVO® is the result of a collaboration between Optiscan and Carl Zeiss Meditec providing live microscopic imaging technology in the field of Neurosurgery. 

More information relating specifically to the ZEISS CONVIVO™ can be found here.

Optiscan has signed a Collaboration Agreement with Australian Clinical Labs (ACL), one of Australia's leading private pathology providers, to support the deployment, evaluation and testing of its InForm™ digital pathology platform. Learn more.

Optiscan is conducting clinical studies with the Royal Melbourne Hospital, one of Australia's leading public teaching hospitals, to evaluate its InVue™ and InForm™ devices in breast cancer surgery. Learn more.

Optiscan working with St John of God Murdoch Hospital in Perth on a clinical trial as part of its broader clinical program evaluating the company’s imaging technologies in head and neck cancer surgery. Learn more.

Optiscan is collaborating with Arizona Animal Hospital, a leading companion animal practice in the United States, as part of the clinical evaluation and early commercial introduction of the Optiscan InSpecta™ device. Learn more.

Optiscan is collaborating with the University of Minnesota College of Veterinary Medicine, one of the leading veterinary teaching and research institutions in the United States, to advance the clinical evaluation of Optiscan InSpecta™ and explore new veterinary applications for real-time imaging technology. Learn more.

Optiscan has a long history with Monash University, with our original technology created at the prestigious university. More recently, Optiscan has entered into an agreement with Monash University to progress its project to create a scope-agnostic GI flexible endomicroscope and next-generation AI technology. Learn more.

Optiscan is collaborating with University Medical Center Mainz in Germany on a pre-clinical gastrointestinal study, supporting evaluation of the company’s endomicroscopy technology in GI applications. Learn more about University Medical Center Mainz here. Learn more.